Information for investors

The company is holding an Initial Public Offering

Medicortex Finland Plc has launched an initial public offering (IPO) on 13 June 2022 and intends to apply for listing on Nasdaq First North Growth Market Finland. The IPO is open until 22 June 2022.

The objective of the Offering and the Listing on First North is to improve Medicortex’s financial ability to further the development of its coming diagnostic products for detecting brain injuries. Furthermore, the Offering is aimed to broaden the ownership base of the Company’s Shares and to offer existing and new shareholders the ability to trade shares in Medicortex as well as to improve the quality of Medicortex’s Shares as a method of payment in the event of potential strategic acquisitions.

For more information about the IPO and how to invest, please see the company's official IPO webpage: https://sijoittajat.medicortex.fi

You may also directly go to the Offering's subscription place, Nordnet Bank AB's page:

Finnish: https://www.nordnet.fi/fi/medicortex

Swedish: https://www.nordnet.se/se/medicortex

Danish: https://www.nordnet.dk/dk/medicortex

Information for investors

1. Why to invest
   
2. How the Medicortex test kit would benefit people
   
3. Get to know more by viewing our PowerPoint Presentation and Executive summary
4. Here you can find our Financials
   
   
   
   

Keep following investors updates in your inbox

Sign up to Medicortex email list. 

Note: This information may not be published or distributed directly or indirectly in the United States, Australia, Canada, Hong Kong, South Africa, Singapore, New Zealand, Japan or in any other country where disclosure or dissemination would be unlawful.

Investments always include risks. Invest responsibly!